Purpose of review
Anti-nonGal xenoantibodies are a major barrier to the survival of genetically modified porcine xenografts. This review summarizes the contribution of anti-nonGal xenoantibodies to the activation of porcine endothelial cells and graft rejection, and further provides an update on recent advancements in defining the unique features of anti-nonGal xenoantibody structure.
Recent findings
Anti-nonGal xenoantibodies pre-exist at low levels in humans and nonhuman primates, and are notably absent in neonates. Exposure of nonhuman primates to a1,3galactosyltransferase gene knockout endothelial cells initiates an induced xenoantibody response that is restricted and encoded by the germline immunoglobulin heavy chain gene IGHV3-21. The target xenoantigen remains undetermined, but several candidate targets have been proposed, including carbohydrate xenoantigens. New advancements in molecular modeling provide insight on the mechanism by which xenoantibodies bind to structurally related carbohydrates. Summary Genetic manipulation of porcine donors has significantly prolonged the survival of grafts placed into nonhuman primate recipients, but anti-nonGal xenoantibodies and thrombosis limit the ability of these grafts to function on a long-term basis. Recent developments defining pre-existing anti-nonGal xenoantibody levels, the restriction in the anti-nonGal xenoantibody response and the identification of key sites defining xenoantibody-carbohydrate interactions now provide the information necessary to develop new approaches to preventing xenoantibody-mediated rejection. when immunosuppressed baboons received porcine GalT-KO cardiac xenografts has recently been described in detail [8 ,9] . The grafts survived for up to 6 months with a median survival time of 78 days prior to undergoing rejection. At rejection, the grafts were characterized by thrombotic microangiopathy, myocardial ischemia, necrosis and focal interstitial hemorrhage. Immunoglobulin (Ig)M and IgG xenoantibodies as well as complement were deposited onto the graft and the severity of rejection could be correlated with the degree of IgM, IgG and complement (C3, C4d and C5b-9) deposition. Cell death and endothelial cell activation was associated with antibody and complement deposition, which contributed to platelet-fibrin thrombi formation. This finding suggests that thrombotic microangiopathy in GalT-KO xenografts is associated with anti-nonGal antibody-mediated rejection [8 ,9] . The pathology of GalT-KO heart xenograft rejection included acute humoral xenograft rejection, acute cellular xenograft rejection and chronic rejection [9] . Chronic humoral rejection was likely to be the dominant mechanism by which chronic xenograft vasculopathy developed in this group of animals.
Non-Gal antibodies that bound to the graft were primarily directed against endothelial cells [9] . Xenoantigens as well as complement-activating and inhibitory elements that are expressed on the surface of endothelial cells before and after exposure to xenoantibodies are of major interest to investigators seeking to understand and prevent the process of rejection. Saethre et al. [14] have shown that preformed anti-nonGal xenoantibodies comprise approximately 10% of the total anti-porcine xenoantibodies present in human sera and that they can activate porcine endothelial cells as shown by upregulation of E-selectin expression.
Approaches designed to prevent the activation of porcine xenograft endothelium and the resulting intravascular coagulation that occurs in vivo include overexpression of complement regulatory factors and anticoagulant proteins on the GalT-KO background [15] . Studies [16, 17 ] done in small animal models transgenic for human a-1,2-fucosyltransferase, human decay-accelerating factor (hDAF) and/or CD59 support the concept that multiple transgenic modifications are beneficial. Mouse hearts modified to synergistically express more than one genetic modification were perfused ex vivo with human plasma and the survival time and cardiac function were examined [17 ] . Deposition of IgM, C3c or C9 on the cardiac vascular endothelial cells of the human a-1,2-fucosyltransferase, human a-1,2-fucosyltransferase/CD59 and/or hDAF transgenic mice with multiple genetic modifications was markedly decreased as compared with controls. Survival time was longer and function was better in cotransgenic mice [17 ] .
The role of multiple transgenic modifications in delaying the onset of antibody-mediated rejection is currently being addressed in larger animal models in a number of laboratories. Kelishadi et al. [18] transplanted kidneys from GalT-KO pigs expressing hDAF into baboons. Failure of these grafts was not associated with classic acute humoral xenograft rejection, but the xenograft recipients died secondary to the development of consumptive coagulopathy with platelet aggregation, thrombocytopenia, anemia and bleeding. The grafts remained functional [18] . Investigation into the role of complement regulatory factors and anticoagulant proteins expressed on the endothelium of GalT-KO pigs suggests that complement regulation is not enough to prevent endothelial cell activation and intravascular coagulation. GalT-KO pigs transgenic for a combination of complement regulators and anticoagulants, such as hDAF and CD39, may be more resistant to the effects of acute humoral xenograft rejection and consumptive coagulopathy.
Preformed anti-nonGal xenoantibodies
There is now evidence from our laboratory and others that GalT-KO xenoantibodies preexist in humans and nonhuman primates at significantly lower levels than anti-Gal xenoantibodies [11 ,12-14] . As a threshold level of xenoreactive antibodies is necessary to initiate xenograft rejection [19] , it is not surprising that hyperacute rejection of GalT-KO xenografts has not been reported. Biopsy specimens of GalT-KO cardiac xenografts studied as soon as 1 h after transplant demonstrated clear evidence of IgM deposition on the grafts, whereas IgG was only weakly positive or negative [9] . IgM anti-nonGal xenoantibodies pre-exist in nonhuman primates as well as in healthy humans. These IgM anti-nonGal xenoantibodies may be responsible for initiating xenograft rejection when they reach sufficient levels after placement of the xenograft. We found that in naive rhesus monkeys, preexisting IgM xenoantibodies bound to an average of 8% of GalT-KO pig cells, considerably lower than the 78-99% binding of preexisting IgM xenoantibodies to wild-type pig cells that express the gal carbohydrate [11 ] . Interestingly, cytotoxic natural anti-nonGal xenoantibodies are either absent or present in very low levels in infant baboons and humans [12] . Anti-Gal xenoantibodies, in contrast, develop during the first 3 months after birth and continue to rise thereafter [12] . Transplantation of GalT-KO pig cells or organs may, therefore, be more successful if done shortly after birth when xenoantibodies that represent a major immunological barrier to graft survival are lacking and the recipient may be amenable to the induction of xenograft tolerance.
The target
The xenoantigen target(s) that initiate anti-nonGal xenoantibody responses have not been identified. Byrne et al. [20] recently used western blotting and proteomic analysis to identify a series of potential targets of induced anti-nonGal xenoantibodies in nonhuman primates. IgG xenoantibodies eluted from GalT-KO hearts at rejection or induced by transplantation with CD46 transgenic pig grafts bound to fibronectin, MG-160 (human Golgi apparatus protein-1), various cytoplasmic proteins, several heat shock proteins, annexin and vimentin. Additional pig endothelial cell antigens were identified but remain to be characterized.
Several other laboratories have data to suggest that a carbohydrate xenoantigen may contribute to anti-nonGal xenoantibody-mediated rejection. The Hanganutziu-Deicher antigen, N-glycolylneuraminic acid (NeuGc), is a sialic acid present on animal cells but absent on human cells. Humans lack NeuGc due to a mutation in the gene encoding CMP (cytidine monophosphate)-Nacetylneuraminic acid hydroxylase-NeuAc hydroxylase, an enzyme required for its synthesis [21] . Saethre et al. [14] reported that anti-Hanganutziu-Deicher antibodies are present in each of 80 human serum samples examined and that human serum induced activation of GalT-KO endothelial cells could be correlated with anti-Hanganutziu-Deicher IgM and IgG antibody levels. These findings suggest the Hanganutziu-Deicher xenoantigen may be a relevant carbohydrate target to which anti-nonGal xenoantibodies pre-exist in humans.
Other potential xenoantigens include low levels of the Gal carbohydrate. Milland et al. [22] recently showed that low levels of gal carbohydrate expression remain on galactosyltransferase-deficient mouse cells and are encoded by an enzyme called isoglobotrihexosylceramide (iGb3) synthase. It has been postulated that anti-nonGal xenoantibodies may bind to a residual gal carbohydrate expressed on GalT-KO pig cells as a consequence of iGb3 synthase expression. We examined whether iGb3 synthase might be expressed in GalT-KO pig cells using primers designed to identify conserved regions in the galactosyltransferase 2 gene (A3galt2 or iGb3 synthase) in humans, rats and mice [11 ] . Our data confirmed that expression of the gene encoding this transferase is detected in GalT-KO mice but we did not detect expression of this gene in GalT-KO pig cells, GalT-KO fetal pig fibroblasts or in minipig kidney cells (MPK) from wild-type pigs. These data suggest that iGb3 synthase is not expressed in GalT-KO pig cells. Diswall et al. [23, 24 ] examined small intestine and pancreatic samples from GalT-KO pigs using thin-layer chromatography, and similarly found that Gala1,3Galterminated glycolipids were eliminated by knockout of the porcine a1,3-galactosyltransferase gene. Interestingly, xenoantibodies induced after immunization do show an increase in binding to purified Gala1-3Galb1-4GlcNAc, but not to Gala1-3Galb1-4Glc or to N-acetyllactosamine [11 ] . A substantial increase in binding of anti-nonGal xenoantibodies from posttransplant samples was demonstrated when GalT-KO cells were transduced to express the Gal carbohydrate [11 ] . The data suggest that a substantial proportion of anti-nonGal xenoantibodies can bind to a xenoantigen that is similar in structure to, but distinct from, the gal carbohydrate, supporting the hypothesis that carbohydrate xenoantigens play a key role in the xenoantibody response to GalT-KO cells.
The structure of anti-nonGal xenoantibodies Analysis of xenoantibody structure will allow the molecular basis for xenoantibody-carbohydrate interactions to be understood. This is an important first step in the development of novel ways to prevent xenograft rejection mediated by anti-nonGal xenoantibodies. The structure and sequence of immunoglobulin genes encoding anti-nonGal xenoantibodies in the GalT-KO model has recently been reported by our laboratory [11 ] . These anti-nonGal xenoantibodies are restricted and are encoded by the immunoglobulin heavy chain gene IGHV3-21. This germline progenitor is not expressed at high levels in the natural antibody repertoire and the most-closely related genes encode antibodies to glycolipids and/or human antibodies to the Gal/GalNAc lectin expressed on the intestinal parasite Entamoeba histolytica [25] . Anti-nonGal xenoantibodies differ in D-J usage when compared with antibodies that encode anti-glycolipid responses in humans [26] . IgV H gene usage in the normal repertoire of primates is not restricted [27, 28] .
Anti-nonGal xenoantibodies have been studied in other models, for example, after transplantation of hDAF transgenic pig organs into monkeys treated with GAS914. This treatment regimen results in the expanded use of xenoantibodies encoded by IGHV3-11Ã03 [29] . The germline progenitors IVHG3-21 and IGHV3-11Ã03 are 91% similar to each other and differ from the IGHV3-11 Ã 01 allele encoding anti-Gal xenoantibodies by less than 5% [30, 31] . This finding suggests to us that the structure of the target xenoantigens is similar. The importance of differences in these antibodies at positions 31, 33, 50 and 58 which are key sites of xenoantibody-carbohydrate interaction identified by computer-simulated models remains to be determined [32] (Fig. 1) . These sites may be important for binding site affinity, specificity or both as predicted by the molecular model. At the present time, our data support the concept that 'signature' antibody repertoires define xenoantibody responses, but the immune response to xenoantigens is initiated by germline progenitors that are evolutionarily and structurally related.
Similar findings were recently reported using a site mapping technique to compare antibody-carbohydrate interactions in the mouse [33, 34 ] . Agostino et al. [34 ] studied antibodies that bind to carbohydrate xenoantigens and identified four key regions of relevance for antigen interaction. Specific amino acids within the CDR1, CDR2 and CDR3 of the heavy chain and select amino acids in the light chain rather than entire stretches of the CDR regions are important for xenoantibody-carbohydrate interactions [35] . The amino acids located at these key sites and the configuration of the carbohydrate may impact the manner in which antibodies that are closely related in structure bind to different carbohydrates [36] . Binding affinity can be further optimized by charged amino acids in the CDR3 region of the immunoglobulin heavy-chain gene [37] .
Conclusion
Anti-nonGal xenoantibodies do not cause hyperacute rejection of GalT-KO xenografts but do contribute to the acute humoral xenograft rejection of these organs. The combination of transgenic modifications on the GalT-KO background appears to be beneficial but insufficient for long-term xenograft survival. Recent advances in xenoantibody structure and the identification of a restriction in Ig gene usage will provide new opportunities to design novel reagents that may be combined with current approaches to minimize the xenoantibody response in a targeted manner. The amino acid translation of the complementarity determining regions of the IgV H genes encoding induced anti-Gal and anti-nonGal IgM xenoantibodies in monkeys are aligned with their closest human germline progenitor. Antigal xenoantibodies were induced after transplantation of wild-type pig grafts [31] . Anti-nonGal xenoantibodies (hDAF non-Gal) were induced after transplantation of hDAF transgenic pig grafts in nonhuman primates treated with GAS914 [29] . The amino acid sequence of the CDR regions of anti-nonGal xenoantibodies induced after immunization of nonhuman primates with GalT-KO endothelial cells are identified as GalT-KO non-Gal [11 ] . Amino acids located at contact sites predicted by computer-simulated models to be relevant for xenoantibody-carbohydrate interaction are identified in bold lettering [32] . GalT-KO, a1,3-galactosyltransferase gene knockout; hDAF, human decay-accelerating factor.
